Insightful Trader Tips
  • Finances
  • World News
  • Investing
  • Stock
Investing

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis

by December 19, 2024
December 19, 2024

Cardiol Therapeutics President and CEO, David Elsley

PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company’s lead oral drug, CardiolRx, which is entering a late-stage Phase III clinical trial, MAVERIC, for patients with recurrent pericarditis who are at high risk for recurrence.

Cardiol Therapeutics is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Elsley states, ‘CardiolRx is uniquely positioned to address critical gaps in the current treatment options for recurrent pericarditis.’

During a discussion with PRISM MarketView, Elsley describes the market opportunity for its lead drug candidate, its key differentiators from other treatments, the recent Phase II MAvERIC-Pilot study results, the company’s financial position and key upcoming milestones. ‘With its potential to be safer, more cost-effective, and disease-modifying, CardiolRx could significantly improve the standard of care for the thousands of patients living with recurrent pericarditis,’ Elsley commented regarding the potential positive impacts and market opportunity for its lead drug candidate.

The full interview can be found at: https://prismmarketview.com/cardiol-therapeutics-nasdaq-crdl-accelerates-late-stage-trial-targeting-1b-recurrent-pericarditis-market-aiming-to-transform-heart-disease-care/

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.

Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration (‘US FDA’) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the Phase II MAvERIC-Pilot study (NCT05494788), the Phase II/III MAVERIC-2 trial, and the planned Phase III MAVERIC-3 trial. The ARCHER trial (NCT05180240) is a Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, which includes recurrent pericarditis.

Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.

For more information about Cardiol Therapeutics, please visit cardiolrx.com .

About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter .

PRISM MarketView does not provide investment advice.

Disclaimer
This communication was produced by PRISM MarketView, an affiliate of PCG Advisory Inc., (together ‘PCG’). PCG is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. PCG may be compensated by respective clients for publicizing information relating to its client’s securities. See www.pcgadvisory.com/disclosures .

Contact: PRISM MarketView
info@prismmarketview.com
646-863-6341

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d1b5e784-ae3d-4783-a994-4ac06d521bef

News Provided by GlobeNewswire via QuoteMedia

This post appeared first on investingnews.com
previous post
Forum Comments on Share Price
next post
Former Assad security forces hand in weapons to new Syrian government

Related Posts

Silver47 Announces Graduation to Tier 1 Status on...

May 22, 2025

Harvest Gold Soil Sampling Program Reveals Several New...

May 22, 2025

Element79 Gold Corp. Comments on Peruvian Government Reform...

May 22, 2025

Element79 Gold Corp. Comments on Peruvian Government Reform...

May 22, 2025

Purepoint Completes Initial Drill Program Along Groomes Lake...

May 22, 2025

Crypto Market Recap: Bitcoin Breaks US$111K, Trump Courts...

May 23, 2025

Forte Minerals Announces Private Placement of up to...

May 23, 2025

Group Eleven Announces Uplisting to OTCQB Market

May 23, 2025

Rio Tinto Partners with Codelco to Develop Lithium...

May 23, 2025

Thick High-Grade Graphite Drilling Results In New Zone

May 22, 2025

Silver47 Announces Graduation to Tier 1 Status on...

May 22, 2025

Harvest Gold Soil Sampling Program Reveals Several New...

May 22, 2025

Element79 Gold Corp. Comments on Peruvian Government Reform...

May 22, 2025

Element79 Gold Corp. Comments on Peruvian Government Reform...

May 22, 2025

Purepoint Completes Initial Drill Program Along Groomes Lake...

May 22, 2025

Crypto Market Recap: Bitcoin Breaks US$111K, Trump Courts...

May 23, 2025

Forte Minerals Announces Private Placement of up to...

May 23, 2025

Group Eleven Announces Uplisting to OTCQB Market

May 23, 2025

Rio Tinto Partners with Codelco to Develop Lithium...

May 23, 2025

Thick High-Grade Graphite Drilling Results In New Zone

May 22, 2025

Investing

  • Crypto Market Recap: Bitcoin Breaks US$111K, Trump Courts Memecoin Megadonors

    May 23, 2025
  • Forte Minerals Announces Private Placement of up to C$2.4 Million

    May 23, 2025
  • Group Eleven Announces Uplisting to OTCQB Market

    May 23, 2025
  • Rio Tinto Partners with Codelco to Develop Lithium Project in Chile

    May 23, 2025
  • Thick High-Grade Graphite Drilling Results In New Zone

    May 22, 2025

Disclaimer: InsightfulTraderTips.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    • About us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 InsightfulTraderTips.com All Rights Reserved.

    Insightful Trader Tips
    • Finances
    • World News
    • Investing
    • Stock
    Insightful Trader Tips
    • Finances
    • World News
    • Investing
    • Stock
    Copyright © 2025 InsightfulTraderTips.com All Rights Reserved.